Drug distribution in man:: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine

被引:45
作者
Gulyás, B [1 ]
Halldin, C
Sóvágó, J
Sandell, J
Cselényi, Z
Vas, A
Kiss, B
Kárpáti, E
Farde, L
机构
[1] Karolinska Hosp, Dept Clin Neurosci, Psychol Sect, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden
[3] Univ Debrecen, Fac Med, Dept Neurol, Debrecen, Hungary
[4] Chem Works Gedeon Richter Ltd, Budapest, Hungary
关键词
positron emission tomography; drug distribution; vinpocetine; humans; brain;
D O I
10.1007/s00259-002-0823-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Direct information on the distribution of a drug requires measurements in various tissues. Such data have until now been obtained in animals, or have indirectly been calculated from plasma measurements in humans using mathematical models. Here we suggest the use of positron emission tomography (PET) as a method to obtain direct measurements of drug distribution in the human body. The distribution in body and brain of vinpocetine, a neuroprotective drug widely used in the prevention and treatment of cerebrovascular diseases, was followed after oral administration. Vinpocetine was labelled with carbon-11 and radioactivity was measured by PET in stomach, liver, brain and kidney in six healthy volunteers. The radioactivity in blood and urine as well as the fractions of [C-11]vinpocetine and labelled metabolites in plasma were also determined. After oral administration, [C-11]vinpocetine appeared immediately in the stomach and within minutes in the liver and the blood. In the blood the level of radioactivity continuously increased until the end of the measurement period, whereas the fraction of the unchanged mother compound decreased. Radioactivity uptake and distribution in the brain were demonstrable from the tenth minute after the administration of the labelled drug. Brain distribution was heterogeneous, similar to the distribution previously reported after intravenous administration. These findings indicate that vinpocetine, administered orally in humans, readily enters the bloodstream from the stomach and gastrointestinal tract and, consequently, passes the bloodbrain barrier and enters the brain. Radioactivity from [C-11]vinpocetine was also demonstrated in the kidneys and in urine, indicating that at least a part of the radioactive drug and labelled metabolites is eliminated from the body through the kidneys. This study is the first to demonstrate that PET might be a useful, direct and non-invasive tool to study the distribution and pharmacokinetics of orally administered labelled CNS drugs in the living human body.
引用
收藏
页码:1031 / 1038
页数:8
相关论文
共 19 条
[1]  
[Anonymous], 1995, DEV NUCL MED
[2]   A systematic review of vinpocetine therapy in acute ischaemic stroke [J].
Bereczki, D ;
Fekete, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (05) :349-352
[3]   Cochrane report - A systematic review of mannitol therapy for acute ischemic stroke and cerebral parenchymal hemorrhage [J].
Bereczki, D ;
Liu, M ;
do Prado, GF ;
Fekete, I .
STROKE, 2000, 31 (11) :2719-2722
[4]   HEAD FIXATION DEVICE FOR REPRODUCIBLE POSITION ALIGNMENT IN TRANSMISSION CT AND POSITRON EMISSION TOMOGRAPHY [J].
BERGSTROM, M ;
BOETHIUS, J ;
ERIKSSON, L ;
GREITZ, T ;
RIBBE, T ;
WIDEN, L .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1981, 5 (01) :136-141
[5]   Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine [J].
Bönöczk, P ;
Gulyás, B ;
Adam-Vizi, V ;
Nemes, A ;
Kárpáti, E ;
Kiss, B ;
Kapás, M ;
Szántay, C ;
Koncz, I ;
Zelles, T ;
Vas, A .
BRAIN RESEARCH BULLETIN, 2000, 53 (03) :245-254
[6]   Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial [J].
Feigin, VL ;
Doronin, BM ;
Popova, TF ;
Gribatcheva, EV ;
Tchervov, DV .
EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (01) :81-85
[7]  
GREITZ T, 1980, NEURORADIOLOGY, V19, P1
[8]   Brain uptake and plasma metabolism of [11C]vinpocetine:: A preliminary PET study in a cynomolgus monkey [J].
Gulyás, B ;
Halldin, C ;
Karlsson, P ;
Chou, YH ;
Swahn, CG ;
Bönöck, P ;
Paróczai, M ;
Farde, L .
JOURNAL OF NEUROIMAGING, 1999, 9 (04) :217-222
[9]  
GULYAS B, 2002, IN PRESS ACTA NEUROL
[10]  
HALLDIN C, 1990, APPL RADIAT ISOTOPES, V41, P669